natgillin/translations-raw huggingface dataset:
Caution should be exercised in patients with risk factors for QT prolongation, including patients with a personal or family history of QT prolongation, congestive heart failure, bradyarrhythmias and electrolyte abnormalities. 
uključujući bolesnike koji u osobnoj ili obiteljskoj anamnezi imaju produljenje QT-a, kongestivno zatajenje srca, bradiaritmije i poremećaje elektrolita.
For these reasons, the combined administration of ciclosporin and tacrolimus is not recommended and care should be taken when administering tacrolimus to patients who have previously received ciclosporin (see sections 4.2 and 4.4). 
Zbog toga se ne preporučuje kombinirana primjena ciklosporina i takrolimusa te je potreban oprez kad se takrolimus primjenjuje u bolesnika koji su prethodno primali ciklosporin (vidjeti dijelove 4.2 i 4.4).
Posterior reversible encephalopathy syndrome (PRES) Patients treated with tacrolimus have been reported to develop posterior reversible encephalopathy syndrome (PRES). 
Zabilježeno je da bolesnici liječeni takrolimusom razvijaju sindrom posteriorne reverzibilne encefalopatije (engl.
Tacrolimus is a low-clearance substance. 
Izlučivanje Takrolimus je tvar s niskim klirensom.
hirsutism Metabolism and nutrition disorders very common: 
Poremećaji metabolizma i prehrane Vrlo često:
High potassium intake or potassium-sparing diuretics should be avoided (see section 4.5). 
Treba izbjegavati uzimanje velikih količina kalija ili diuretika koji štede kalij (vidjeti dio 4.5).
The initial oral per protocol dose of tacrolimus was 0.2 mg/kg/day with subsequent dose adjustments to target trough levels of 8 to 15 nanogram/ml by Day 5 and 5 to 10 nanogram/ml after Month 6. 
0,2 mg/kg na dan s naknadnim prilagodbama doze do ciljnih najnižih razina od 8 do 15 nanogram/ml do 5. dana i 5 do 10 nanogram/ml nakon 6 mjeseci.
Increased tacrolimus doses, supplemental corticosteroid therapy, and introduction of short courses of mono-/polyclonal antibodies have all been used to manage rejection episodes. 
Za liječenje epizoda odbacivanja koristile su se više doze takrolimusa, nadomjesna kortikosteroidna terapija i kratkotrajne terapije monoklonalnim ili poliklonalnim protutijelima.
Prophylaxis of transplant rejection in adult and paediatric, kidney, liver or heart allograft recipients. 
Profilaksa odbacivanja alogenog presatka u odraslih i pedijatrijskih bolesnika kojima su presađeni bubreg, jetra ili srce.
In particular, you should tell your doctor if you are taking or have recently taken medicines like: - antifungal medicines and antibiotics, particularly so-called macrolide antibiotics, used to treat infections e.g. ketoconazole, fluconazole, itraconazole, voriconazole, clotrimazole, and isavuconazole, erythromycin, clarithromycin, josamycin, and rifampicin - letermovir, used to prevent illness caused by CMV (human cytomegalovirus) - HIV protease inhibitors (e.g. ritonavir, nelfinavir, saquinavir), the booster medicine cobicistat, 
Osobito trebate obavijestiti svog liječnika ako uzimate ili ste nedavno uzimali lijekove kao što su: - antimikotici i antibiotici, osobito takozvani makrolidni antibiotici, koji se primjenjuju za liječenje infekcija, npr. ketokonazol, flukonazol, itrakonazol, vorikonazol, klotrimazol i izavukonazol, eritromicin, klaritromicin, josamicin i rifampicin
Prophylaxis of heart transplant rejection 
Profilaksa odbacivanja presatka srca
metabolic acidoses, other electrolyte abnormalities, hyponatraemia, fluid overload, hyperuricaemia, hypomagnesaemia, hypokalaemia, hypocalcaemia, appetite decreased, hypercholesterolaemia, hyperlipidaemia, hypertriglyceridaemia, hypophosphataemia uncommon: 
preopterećenje tekućinom, hiperuricemija, hipomagnezijemija, hipokalijemija, hipokalcijemija, smanjeni apetit, hiperkolesterolemija, hiperlipidemija, hipertrigliceridemija, hipofosfatemija
How to store Modigraf 
Kako čuvati Modigraf
During the initial post-transplant period, monitoring of the following parameters should be undertaken on a routine basis: blood pressure, ECG, neurological and visual status, fasting blood glucose levels, electrolytes (particularly potassium), liver and renal function tests, haematology parameters, coagulation values, and plasma protein determinations. 
elektrokardiogram, neurološki status i status vida, razinu glukoze u krvi natašte, elektrolite (osobito kalij), testove jetrene i bubrežne funkcije, hematološke parametre, koagulacijske vrijednosti i proteine u plazmi.
The frequency of blood level monitoring should be based on clinical needs. 
Razinu u krvi treba određivati onoliko često koliko je to klinički potrebno.
Prograf has been used in lung-transplanted patients at an initial oral dose of 0.10 - 0.15 mg/kg/day, in pancreas-transplanted patients at an initial oral dose of 0.2 mg/kg/day and in intestinal transplantation at an initial oral dose of 0.3 mg/kg/day. 
Prograf se primjenjivao u bolesnika s presađenim plućima u početnoj peroralnoj dozi od 0,10 do 0,15 mg/kg na dan, u bolesnika s presađenom gušteračom u početnoj peroralnoj dozi od 0,2 mg/kg na dan i u bolesnika s presađenim crijevima u početnoj peroralnoj dozi od 0,3 mg/kg na dan.
Systemically available tacrolimus is metabolised by hepatic CYP3A4. 
Sistemski dostupan takrolimus se metabolizira putem CYP3A4 u jetri.
This medicinal product should only be prescribed, and changes in immunosuppressive therapy initiated, by physicians experienced in immunosuppressive therapy and the management of transplant patients. 
4.2 Doziranje i način primjene Ovaj lijek smiju propisivati i započetu imunosupresivnu terapiju mijenjati samo liječnici s iskustvom u primjeni imunosupresivne terapije i liječenju bolesnika s presađenim organom.
Benign as well as malignant neoplasms including EBV-associated lymphoproliferative disorders and skin malignancies have been reported in association with tacrolimus treatment. 
Zabilježene su dobroćudne kao i zloćudne novotvorine uključujući limfoproliferativne poremećaje povezane s EBV virusom i kožne zloćudne promjene povezane s liječenjem takrolimusom.
Tacrolimus was started as continuous intravenous infusion at a dose of 0.01 to 0.03 mg/kg/day and oral tacrolimus was administered at a dose of 0.05 to 0.3 mg/kg/day. 
Takrolimus je započet kao kontinuirana intravenska infuzija u dozi od 0,01 do 0,03 mg/kg na dan, a peroralni takrolimus je primjenjen u dozi od 0,05 do 0,3 mg/kg na dan.
Intestinal transplantation 
Transplantacija pluća
hypertension, renal or hepatic dysfunction, infections, fluid overload, and oedema. 
uzimanje kortikosteroida, hipertenziju, poremećaj funkcije bubrega ili jetre, infekcije, preopterećenje tekućinom i edeme.
Tell your doctor immediately if during treatment you suffer from: problems with your vision such as blurred vision, changes in colour vision, difficulty in seeing detail or if your field of vision becomes restricted. 
probleme s vidom kao što su zamagljen vid, promjene vida u boji, otežano uočavanje detalja, ili ako
Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult and paediatric patients. 
Liječenje odbacivanja alogenog presatka u odraslih i pedijatrijskih bolesnika u slučaju rezistencije na liječenje drugim imunosupresivnim lijekovima.
Tacrolimus has been shown to increase the blood level of phenytoin. 
Pokazalo se da takrolimus povećava razinu fenitoina u krvi.
These may worsen kidney or nervous system problems when taken together with Modigraf. 
Kad se ti lijekovi uzimaju zajedno s Modigrafom mogu pogoršati tegobe s bubrezima ili živčanim sustavom.
Treatment of allograft rejection after kidney or liver transplantation - adults and paediatric patients For conversion from other immunosuppressants to twice daily Modigraf, treatment should begin with the initial oral dose recommended for primary immunosuppression. 
Za prebacivanje s drugih imunosupresiva na Modigraf dvaput na dan, liječenje treba započeti početnom peroralnom dozom koja se preporučuje za primarnu imunosupresiju.
Modigraf is a granular formulation of tacrolimus, for twice-a-day administration. 
Modigraf je granularni oblik takrolimusa za primjenu dvaput na dan.
Similarly, for conversion of patients from Prograf capsules to Modigraf granules, the total daily Modigraf dose should preferably be equal to the total daily Prograf dose. 
Slično tome, za prebacivanje bolesnika s Prograf kapsula na Modigraf granule ukupna dnevna doza
hepatic failure Skin and subcutaneous tissue disorders common: 
Poremećaji kože i potkožnog tkiva Često:
febrile disorders, pain and discomfort, asthenic conditions, oedema, body temperature perception disturbed uncommon: 
febrilni poremećaji, bol i nelagoda, astenijska stanja, edemi, poremećen doživljaj tjelesne temperature
Patients treated with tacrolimus have been reported to develop Epstein-Barr Virus (EBV)-associated lymphoproliferative disorders (see section 4.8). 
Epstein-Barrovim virusom (EBV) (vidjeti dio 4.8).
ischaemic coronary artery disorders, tachycardia uncommon: 
ishemijski poremećaji koronarnih arterija, tahikardija
venoocclusive liver disease, hepatic artery thrombosis very rare: 
venookluzivna bolest jetre, tromboza jetrene arterije
Patients should be maintained on a single formulation of tacrolimus with the corresponding dosing regimen; alterations in formulation or regimen should only take place under the close supervision of a transplant specialist (see sections 4.4 and 4.8). 
Promjene u formulacijama ili režimu davanja smiju se provesti samo pod strogim nadzorom specijalista transplantacijske medicine (vidjeti dijelove 4.4 i 4.8).
Modigraf 0.2 mg granules for oral suspension Modigraf 1 mg granules for oral suspension 
Modigraf 0,2 mg granule za oralnu suspenziju Modigraf 1 mg granule za oralnu suspenziju
pancreatic pseudocyst, subileus Hepatobiliary disorders common: 
pseudocista gušterače, subileus
Patients should be maintained on a single formulation of tacrolimus with the corresponding daily dosing regimen; alterations in formulations or regimen should only take place under the close supervision of a transplant specialist (see sections 4.2 and 4.8). 
Promjene u formulacijama ili režimu davanja smiju se provesti samo pod strogim nadzorom specijalista za transplantacijsku medicinu (vidjeti dijelove 4.2 i 4.8).
heart failures, ventricular arrhythmias and cardiac arrest, supraventricular arrhythmias, cardiomyopathies, ventricular hypertrophy, palpitations rare: 
zatajenje srca, ventrikularne aritmije i srčani arest, supraventrikularne aritmije,
Following antibody induction, if Modigraf therapy is initiated orally, the recommended starting dose is 0.10 - 0.30 mg/kg/day administered as 2 divided doses (e.g. morning and evening). 
Ako se nakon indukcije protutijela terapija Modigrafom započne peroralno, preporučena početna doza je 0,10 do 0,30 mg/kg na dan podijeljena u 2 odvojene doze (npr. ujutro i navečer).
Tacrolimus was started as continuous intravenous infusion at a dose of 0.05 mg/kg/day and oral tacrolimus was administered at a dose of 0.1 to 0.3 mg/kg/day with subsequent dose adjustments to target trough levels of 12 to 15 nanogram/ml. 
Takrolimus je započet kao kontinuirana intravenska infuzija u dozi od 0,05 mg/kg na dan, a peroralni takrolimus je primijenjen u dozi od 0,1 do 0,3 mg/kg na dan s naknadnim prilagodbama doze do ciljnih najnižih razina od 12 do 15 nanogram/ml.
Following antibody induction, oral Modigraf therapy should commence at a dose of 0.075 mg/kg/day administered as 2 divided doses (e.g. morning and evening). 
Nakon indukcije protutijela, peroralnu terapiju Modigrafom treba započeti dozom od 0,075 mg/kg na dan podijeljenom u 2 odvojene doze (npr. ujutro i navečer).
Endocrine disorders rare: 
Endokrini poremećaji
In adult liver, kidney and heart transplant patients, values of 4.1 l/h, 6.7 l/h and 3.9 l/h, respectively, have been observed. 
Opaženo je da je taj klirens iznosio 4,1 l/sat u odraslih bolesnika s presatkom jetre, s presatkom bubrega 6,7 l/h i s presatkom srca 3,9 l/sat.
Published clinical experience from a single centre on the use of oral tacrolimus for primary treatment following intestinal transplantation showed that the actuarial survival rate of 155 patients (65 intestine alone, 75 liver and intestine, and 25 multivisceral) receiving tacrolimus and prednisone was 75% at 1 year, 54% at 5 years, and 42% at 10 years. 
(65 samo s presađenim crijevima, 75 s presađenom jetrom i crijevima i 25 s multivisceralnim presatcima) koji su primali takrolimus i prednizon iznosila 75% nakon 1 godine, 54% nakon 5 godina i
rash, pruritus, alopecias, acne, sweating increased uncommon: 
osip, svrbež, alopecija, akne, pojačano znojenje
bile duct disorders, hepatocellular damage and hepatitis, cholestasis and jaundice rare: 
poremećaji žučovoda, hepatocelularno oštećenje i hepatitis, kolestaza i žutica
Therapeutic drug monitoring 
Terapijsko praćenje koncentracije lijeka
Patients are also at an increased risk of infections with viral hepatitis (for example, hepatitis B and C reactivation and de novo infection, as well as hepatitis E, which may become chronic). 
(primjerice, reaktivacija i de novo infekcija virusom hepatitisa B i C, kao i infekcija virusom hepatitisa
diltiazem and verapamil) - anti-arrhythmic medicines (amiodarone) used to control arrhythmia (uneven beating of the heart) - medicines known as “statins” used to treat elevated cholesterol and triglycerides - phenytoin or phenobarbital, used to treat epilepsy - the corticosteroids prednisolone and methylprednisolone, belonging to the class of corticosteroids used to treat inflammations or suppress the immune system (e.g. in transplant rejection) - nefazodone, used to treat depression - Herbal preparations containing St. John's Wort (Hypericum perforatum) or extracts of 
- fenitoin ili fenobarbital, koji se primjenjuju za liječenje epilepsije - kortikosteroidi prednizolon i metilprednizolon, koji pripadaju klasi kortikosteroida koja se primjenjuje za liječenje upala ili potiskivanje imunološkog sustava (npr. kod odbacivanja presatka) - nefazodon, koji se primjenjuje za liječenje depresije - biljni pripravci koji sadrže gospinu travu (Hypericum perforatum) ili ekstrakte biljke Schisandra sphenanthera.
inflammation of the throat, cough, flu-like symptoms - Stomach problems such as inflammation or ulcer causing abdominal pain or diarrhoea, bleeding in the stomach, inflammation or ulcer in the mouth, collection of fluid in the belly, vomiting, 
- želučane tegobe poput upale ili vrijeda koji uzrokuju bol u trbuhu ili proljev, krvarenje u želudac, upala ili vrijed u ustima, nakupljanje tekućine u trbuhu, povraćanje, bol u trbuhu,
CYP3A4 inhibitors potentially leading to increased tacrolimus blood levels Clinically the following substances have been shown to increase tacrolimus blood levels: Strong interactions have been observed with antifungal agents such as ketoconazole, fluconazole, itraconazole, voriconazole, and isavuconazole, the macrolide antibiotic erythromycin, HIV protease inhibitors (e.g. ritonavir, nelfinavir, saquinavir), HCV protease inhibitors (e.g. telaprevir, boceprevir, and the combination of ombitasvir and paritaprevir with ritonavir, when used with and without dasabuvir), or the CMV antiviral letermovir, the pharmacokinetic enhancer cobicistat, and the tyrosine kinase inhibitors nilotinib and imatinib. 
Jake interakcije opažene su s antimikoticima kao što su ketokonazol, flukonazol, itrakonazol, vorikonazol i izavukonazol, makrolidnim antibiotikom eritromicinom, inhibitorima proteaze HIV-a (npr. ritonavir, nelfinavir, sakvinavir), inhibitorima proteaze HCV-a (npr. telaprevir, boceprevir i kombinacija ombitasvira i paritaprevira s ritonavirom, primijenjena s dasabuvirom ili bez njega) ili antivirotikom za liječenje CMV infekcija letermovirom, zatim farmakokinetičkim pojačivačem kobicistatom te inhibitorima tirozin kinaze nilotinibom i imatinibom.
Tacrolimus 
Killorglin
It is an immunosuppressant. 
Modigraf je imunosupresiv.
thromboembolic and ischaemic events, vascular hypotensive disorders, haemorrhage, peripheral vascular disorders uncommon: 
tromboembolijski i ishemijski događaji, krvožilni hipotenzivni poremećaji,
arthralgia, back pain, muscle spasms, pain in extremity uncommon: 
artralgija, bol u leđima, spazam mišića, bol u ekstremitetu
Modigraf 1 mg granules for oral suspension Each sachet contains 1 mg tacrolimus (as monohydrate). 
Modigraf 1 mg granule za oralnu suspenziju Jedna vrećica sadrži 1 mg takrolimusa (u obliku hidrata).
Croscarmellose sodium (E468) 
6.1 Popis pomoćnih tvari laktoza hidrat hipromeloza (E464) karmelozanatrij, umrežena (E468)
This can lead to graft rejection or increased incidence of undesirable effects, including under- or overimmunosuppression, due to clinically relevant differences in systemic exposure to tacrolimus. 
nenamjerni ili nenadzirani prelazak na formulacije takrolimusa s trenutnim ili produljenim oslobađanjem općenito nije siguran jer može dovesti do odbacivanja presatka ili povećanja incidencije nuspojava, uključujući i preslabu ili prejaku imunosupresiju zbog klinički važnih razlika u sistemskoj izloženosti takrolimusu.
Modigraf 0.2 mg granules for oral suspension Each sachet contains 0.2 mg tacrolimus (as monohydrate). 
Modigraf 0,2 mg granule za oralnu suspenziju Jedna vrećica sadrži 0,2 mg takrolimusa (u obliku hidrata).
febrile neutropenia 
povećanje masnog tkiva febrilna neutropenija
It is necessary to consider the clinical condition of the patient when interpreting whole blood levels. 
Kad se tumače razine u punoj krvi potrebno je uzeti u obzir kliničko stanje bolesnika.
Cases of BK virus associated nephropathy, as well as cases of JC virus associated progressive multifocal leukoencephalopathy (PML), have been reported in patients treated with immunosuppressants, including Modigraf. 
U bolesnika liječenih imunosupresivima, uključujući i Modigraf, zabilježeni su slučajevi nefropatije povezane s BK virusom, kao i slučajevi progresivne multifokalne leukoecefalopatije (PML) povezane s JC virusom.
Each sachet of Modigraf 1 mg granules contains 1 mg of tacrolimus (as monohydrate). 
Jedna vrećica Modigraf 1 mg granula sadrži 1 mg takrolimusa (u obliku hidrata).
liver function tests abnormal common: 
poremećeni nalazi testova jetrene funkcije često:
Eye disorders common: 
Poremećaji oka Često:
Lansoprazole and ciclosporin may potentially inhibit CYP3A4-mediated metabolism of tacrolimus and thereby increase tacrolimus whole blood concentrations. 
Lansoprazol i ciklosporin mogu potencijalno inhibirati metabolizam takrolimusa posredovan CYP3A4
Prophylaxis of liver transplant rejection 
Profilaksa odbacivanja presatka jetre
Each sachet of Modigraf 0.2 mg granules contains 0.2 mg of tacrolimus (as monohydrate). 
Jedna vrećica Modigraf 0,2 mg granula sadrži 0,2 mg takrolimusa (u obliku hidrata).
diabetes mellitus, hyperglycaemic conditions, hyperkalaemia common: 
šećerna bolest, hiperglikemijska stanja, hiperkalijemija
Each sachet contains 1 mg tacrolimus (as monohydrate). 
Jedna vrećica sadrži 1 mg takrolimusa (u obliku hidrata).
Read the package leaflet before use. 
NAČIN PRIMJENE LIJEKA Prije uporabe pročitati uputu o lijeku.
Each sachet contains 0.2 mg tacrolimus (as monohydrate). 
Jedna vrećica sadrži 0,2 mg takrolimusa (u obliku hidrata).
acute respiratory distress syndrome Gastrointestinal disorders very common: 
akutni respiratorni distres sindrom
- Obstruction of the gut, increased blood level of the enzyme amylase, reflux of stomach content in your throat, delayed emptying of the stomach - Inflammation of the skin, burning sensation in the sunlight - Joint disorders - Painful menstruation and abnormal menstrual bleeding - Multiple organ failure, flu-like illness, increased sensitivity to heat and cold, feeling of pressure on your chest, jittery or abnormal feeling, weight loss 
- upala kože, osjećaj žarenja na suncu - poremećaji zglobova - bolne menstruacije i poremećeno menstrualno krvarenje - zatajenje brojnih organa, bolest slična gripi, pojačana osjetljivost na toplinu i hladnoću, osjećaj pritiska u prsima, nemir ili nenormalno osjećanje, gubitak na tjelesnoj težini
coagulopathies, pancytopenia, neutropenia, coagulation and bleeding analyses abnormal rare: 
koagulopatije, pancitopenija, neutropenija, poremećeni nalazi koagulacije i krvarenja
Myasthenia 
hipoakuzija
In patients without antibody induction, if tacrolimus therapy is initiated intravenously, the recommended starting dose is 0.03 - 0.05 mg/kg/day (with Prograf 5 mg/ml concentrate for solution for infusion) as a continuous 24-hour infusion targeted to achieve tacrolimus whole blood concentrations of 15 - 25 nanogram/ml. 
Ako se u bolesnika bez indukcije protutijela terapija takrolimusom započne intravenski, preporučena početna doza je 0,03 - 0,05 mg/kg na dan (s Prograf 5 mg/ml koncentratom za otopinu za infuziju) u obliku kontinuirane 24-satne infuzije s ciljem da se postignu koncentracije takrolimusa u punoj krvi od
An initial oral dose of 0.30 mg/kg/day should be administered in 2 divided doses (e.g. morning and evening). 
0,20 do 0,30 mg/kg na dan treba primijeniti u 2 podijeljene doze (npr. ujutro i navečer).
Modigraf 1 mg granules for oral suspension tacrolimus 
Modigraf 1 mg granule za oralnu suspenziju takrolimus
anaemia, thrombocytopenia, leukopenia, red blood cell analyses abnormal, leukocytosis uncommon: 
anemija, trombocitopenija, leukopenija, poremećeni nalazi crvenih krvnih stanica, leukocitoza
Talk to your doctor or pharmacist before taking Modigraf 
Obavijestite svog liječnika ili ljekarnika prije primjene Modigrafa: - ako imate ili ste imali tegobe s jetrom.
Very rare side effects (may affect up to 1 in 10,000 people): - Muscular weakness - Abnormal heart scan - Liver failure - Painful urination with blood in the urine - Increase of fat tissue 
Rijetke nuspojave (mogu se javiti u do 1 na 1000 osoba): - sitna krvarenja u kožu zbog krvnih ugrušaka
Thereafter the cup is rinsed once with the same quantity of water and the rinsings consumed by the patient. 
Nakon toga treba jedanput isprati čašu istom količinom vode koju bolesnik treba popiti.
hearing impaired 
Poremećaji oka
Modigraf 0.2 mg granules for oral suspension tacrolimus 
Modigraf 0,2 mg granule za oralnu suspenziju takrolimus
When tacrolimus is administered intravenously as rapid infusion/bolus injection at a dose of 0.1 to 1.0 mg/kg, QTc prolongation has been observed in some animal species. 
Kada se takrolimus primjenjuje intravenski kao brza infuzija/bolus injekcija pri dozi od 0,1 do 1,0
Highly variable age dependent total body clearance and half life were observed in limited paediatric clinical investigations, especially in early childhood. 
U ograničenim pedijatrijskim kliničkim ispitivanjima, osobito u vrlo male djece, primijećeno je da su ukupni tjelesni klirens i poluvijek vrlo varijabilni i ovise o dobi.
As tacrolimus treatment may be associated with hyperkalaemia, or may increase pre-existing hyperkalaemia, high potassium intake, or potassium-sparing diuretics (e.g. amiloride, triamterene, or spironolactone) should be avoided (see section 4.4). 
Budući da liječenje takrolimusom može biti povezano s hiperkalijemijom ili pojačati već postojeću hiperkalijemiju, potrebno je izbjegavati uzimanje velikih količina kalija ili diuretika koji štede kalij
Mechanism of action and pharmacodynamic effects At the molecular level, the effects of tacrolimus appear to be mediated by binding to a cytosolic protein (FKBP12) which is responsible for the intracellular accumulation of the compound. 
Čini se da su na molekularnoj razini učinci takrolimusa posredovani vezivanjem za protein citosola
Excipients 
sljepoća
Common side effects (may affect up to 1 in 10 people): - Reduction in blood cell counts (platelets, red or white blood cells), increase in white blood cell counts, changes in red blood cell counts (seen in blood tests) - Reduced magnesium, phosphate, potassium, calcium or sodium in the blood, fluid overload, 
- sniženje broja krvnih stanica (krvnih pločica, crvenih ili bijelih krvnih stanica), povećanje broja bijelih krvnih stanica, promjene broja crvenih krvnih stanica (vide se na krvnim pretragama)